Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (46)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Waite, K. A.
Right arrow Articles by Eng, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waite, K. A.
Right arrow Articles by Eng, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2003, Vol. 12, No. 6 679-684
© 2003 Oxford University Press

BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels

Kristin A. Waite1 and Charis Eng1,2,*

1Clinical Cancer Genetics and Human Cancer Genetics Programs, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine and Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, 43210, USA and 2Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, Cambridge, UK

Received December 9, 2002; Accepted January 21, 2003

The tumour suppressor gene PTEN encodes a dual-specificity phosphatase that recognizes protein and phosphatidylinositiol substrates and modulates cellular functions such as migration and proliferation. Germline mutations of PTEN have been shown to cause Cowden syndrome, Bannayan–Riley–Ruvalcaba syndrome and Proteus syndrome. Recently, germline mutations in BMPR1A, the gene encoding the type 1A receptor of bone morphogenetic proteins (BMP) have been found in rare families with Cowden syndrome, suggesting that there may be a link between BMP signaling and PTEN. We thus sought to determine whether BMP2 stimulation alters PTEN protein levels in the breast cancer line, MCF-7. We found that exposure to BMP2 increased PTEN protein levels in a time- and dose-dependent manner. The increase in PTEN protein was rapid and was not due to an increase in new protein synthesis, as cycloheximide treatment did not inhibit BMP2-induced PTEN accumulation, suggesting that BMP2 stimulation inhibited PTEN protein degradation. Indeed, we found that BMP2 treatment of MCF-7 cells decreased the association of PTEN with two proteins in the degradative pathway, UbCH7 and UbC9. These data indicate that BMP2 exposure can regulate PTEN protein levels by decreasing PTEN's association with the degradative pathway. This opens up a new mode of regulating PTEN activity to be investigated further and may explain why BMPR1A can act as a minor susceptibility gene for PTEN mutation negative Cowden syndrome.

* To whom correspondence should be addressed at: Human Cancer Genetics Program, The Ohio State University, 420 W. 12th Avenue, Suite 690TMRF, Columbus, OH 43210, USA. Tel: +1 6142922347; Fax: +1 6146883582 or 6146883205; Email: eng-1{at}medctr.osu.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol. Biol. CellHome page
E. A. Whitcomb, E. J. Dudek, Q. Liu, and A. Taylor
Novel Control of S Phase of the Cell Cycle by Ubiquitin-conjugating Enzyme H7
Mol. Biol. Cell, January 1, 2009; 20(1): 1 - 9.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Knobloch, I. Schmitz, K. Gotz, K. Schulze-Osthoff, and U. Ruther
Thalidomide Induces Limb Anomalies by PTEN Stabilization, Akt Suppression, and Stimulation of Caspase-Dependent Cell Death
Mol. Cell. Biol., January 15, 2008; 28(2): 529 - 538.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
C. Segrelles, M. Moral, C. Lorz, M. Santos, J. Lu, J. L. Cascallana, M. F. Lara, S. Carbajal, A. B. Martinez-Cruz, R. Garcia-Escudero, et al.
Constitutively Active Akt Induces Ectodermal Defects and Impaired Bone Morphogenetic Protein Signaling
Mol. Biol. Cell, January 1, 2008; 19(1): 137 - 149.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Selvendiran, L. Tong, S. Vishwanath, A. Bratasz, N. J. Trigg, V. K. Kutala, K. Hideg, and P. Kuppusamy
EF24 Induces G2/M Arrest and Apoptosis in Cisplatin-resistant Human Ovarian Cancer Cells by Increasing PTEN Expression
J. Biol. Chem., September 28, 2007; 282(39): 28609 - 28618.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Liu, J. Wang, B. Kinzel, M. Mueller, X. Mao, R. Valdez, Y. Liu, and E. Li
Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity
Blood, September 1, 2007; 110(5): 1502 - 1510.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Kobielak, N. Stokes, J. de la Cruz, L. Polak, and E. Fuchs
Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling
PNAS, June 12, 2007; 104(24): 10063 - 10068.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
C. Park, K. Lavine, Y. Mishina, C.-X. Deng, D. M. Ornitz, and K. Choi
Bone morphogenetic protein receptor 1A signaling is dispensable for hematopoietic development but essential for vessel and atrioventricular endocardial cushion formation
Development, September 1, 2006; 133(17): 3473 - 3484.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Teng, A.-N. Sun, X.-C. Pan, G. Yang, L.-L. Yang, M.-R. Wang, and X. Yang
Synergistic Function of Smad4 and PTEN in Suppressing Forestomach Squamous Cell Carcinoma in the Mouse.
Cancer Res., July 15, 2006; 66(14): 6972 - 6981.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. Agrawal and C. Eng
Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer
Hum. Mol. Genet., March 1, 2006; 15(5): 777 - 787.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
A J Bauer and C A Stratakis
The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis
J. Med. Genet., November 1, 2005; 42(11): 801 - 810.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Yang, C. Mao, Y. Teng, W. Li, J. Zhang, X. Cheng, X. Li, X. Han, Z. Xia, H. Deng, et al.
Targeted Disruption of Smad4 in Mouse Epidermis Results in Failure of Hair Follicle Cycling and Formation of Skin Tumors
Cancer Res., October 1, 2005; 65(19): 8671 - 8678.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. Agrawal, R. Pilarski, and C. Eng
Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN
Hum. Mol. Genet., August 15, 2005; 14(16): 2459 - 2468.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
K. A. Waite, M. R. Sinden, and C. Eng
Phytoestrogen exposure elevates PTEN levels
Hum. Mol. Genet., June 1, 2005; 14(11): 1457 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
D. C.I. Goberdhan and C. Wilson
PTEN: tumour suppressor, multifunctional growth regulator and more
Hum. Mol. Genet., October 15, 2003; 12(90002): R239 - 248.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Wu, X. Wang, W. Zhang, W. Reed, J. M. Samet, Y. E. Whang, and A. J. Ghio
Zinc-induced PTEN Protein Degradation through the Proteasome Pathway in Human Airway Epithelial Cells
J. Biol. Chem., July 18, 2003; 278(30): 28258 - 28263.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.